BRAF and Miyoshi myopathy: To confirm whether the BRAF/MAPK pathway-targeting drug-related synergistic interaction set was affected by the basic characteristics of the mutational profile or by the tissue origin of the cell lines, we compared mutation frequencies between the multidrug combined MM cell lines in BRAF-related sets and all 990 GDSC cell lines.